FierceBiotech  Dec 17  Comment 
Johnson & Johnson has signed a deal to use Halozyme Therapeutics' drug delivery platform in its own R&D efforts, agreeing to pay as much as $581 million for the privilege.
GenEng News  Dec 17  Comment 
Janssen has obtained a worldwide license to Halozyme’s Enhanze technology with the goal of developing and commercializing products combining Janssen compounds with Enhanze technology. Enhanze is based on a proprietary recombinant human...
Benzinga  Dec 12  Comment 
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the 37th Annual San Antonio Breast Cancer Symposium (SABCS) today. The first of the presentations includes...
TheStreet.com  Nov 11  Comment 
NEW YORK (TheStreet) -- Shares of Halozyme Therapeutics, Inc.  are sharply down 6.06% to $8.76 in late morning trading Tuesday, after the drug maker released disappointing third quarter earnings late yesterday....
StreetInsider.com  Nov 11  Comment 
ICU Medical (NASDAQ: ICUI) 11% HIGHER ; reported Q3 EPS of $0.66, $0.18 better than the analyst estimate of $0.48. Revenue for the quarter came in at $77.5 million versus the consensus estimate of $73 million. ICU Medical sees FY2014 EPS of...
Benzinga  Nov 10  Comment 
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported financial results Monday for the third quarter ended September 30, 2014. Financial highlights for the third quarter include revenues of $14.6 million, below estimates of $16.45 million and a net...
TechCrunch  Oct 22  Comment 
 The crowdfunded fitness tracker Moov, built by former Apple engineer and HALO game designer Nikola Hu, Microsoft Research vets Meng Li (now Moov CEO) and Tony Yuan, has raised $3 million in new funding in a Series A round led by Banyan Capital....
StreetInsider.com  Oct 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Halozyme+Therapeutics+%28HALO%29+Receives+U.S.+Patent+%27034+Covering+PEGPH20-Related+Treatment/9891827.html for the full story.



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki